Medication info

Npfone Injection (Ibandronic Acid Sodium Hydrate)

Prescription medicationInjectionsIntravenous injection
Ingredient · strength
Ibandronate Sodium Monohydrate›3.375mg / 1 prefilled syringe
Manufacturer / importer
Daehan New Pharm Co., Ltd.
Appearance
A colorless, transparent solution contained in a colorless, transparent glass prefilled syringe with a single-use injection needle attached.
Packaging
3 mL/prefilled syringe (1 vial)
Approval status
Active

MFDS item code 201602315 · Notified 2016.04.25 · Insurance code 669906741

Summary

Main use
Treatment of osteoporosis in postmenopausal women
Who receives it
Adults · Children
Adult administration
Administer 3mg by intravenous injection over 15 - 30 seconds once every 3 months. Patients should take calcium and vitamin D supplements. If a dose is missed on the scheduled dosing date, administer the injection as soon as possible, and then continue regular dosing at 3-month intervals from that date. Patients with hepatic impairment No dose adjustment is necessary. Patients with renal impairment No dose adjustment is necessary for patients with mild or moderate renal impairment whose serum creatinine is 200 µmol/L(2.3mg/dL) or lower, or whose creatinine clearance is 30ml/min or higher. As clinical experience is insufficient in patients whose serum creatinine exceeds 200 µmol/L(2.3mg/dL) or whose creatinine clearance is less than 30ml/min, administration of this medicine is not recommended. Elderly No dose adjustment is necessary.
Child administration
Children and adolescents aged 18 years or younger: Efficacy and safety have not been studied in children aged 18 years or younger.

Ingredients

Manufacturer
Daehan New Pharm Co., Ltd.

Efficacy & effects

Treatment of osteoporosis in postmenopausal women

  • Osteoporosis
View approved original text

This medication is used to treat osteoporosis that occurs in postmenopausal women. Osteoporosis is a condition characterized by weakened bones that are more prone to fractures, and it is particularly common in women after menopause. Taking this medication helps maintain bone strength and reduce fracture risk. Therefore, it is effective in maintaining healthy bones and preventing fractures in postmenopausal women.

How it is given

Adult administration

Administer 3mg by intravenous injection over 15 - 30 seconds once every 3 months. Patients should take calcium and vitamin D supplements. If a dose is missed on the scheduled dosing date, administer the injection as soon as possible, and then continue regular dosing at 3-month intervals from that date. Patients with hepatic impairment No dose adjustment is necessary. Patients with renal impairment No dose adjustment is necessary for patients with mild or moderate renal impairment whose serum creatinine is 200 µmol/L(2.3mg/dL) or lower, or whose creatinine clearance is 30ml/min or higher. As clinical experience is insufficient in patients whose serum creatinine exceeds 200 µmol/L(2.3mg/dL) or whose creatinine clearance is less than 30ml/min, administration of this medicine is not recommended. Elderly No dose adjustment is necessary.

Child administration

Children and adolescents aged 18 years or younger: Efficacy and safety have not been studied in children aged 18 years or younger.

Precautions

This medication must be administered intravenously, and great care should be taken to avoid administering it intra-arterially or around the vein, as it can cause tissue damage. It should not be used in patients with an allergic reaction to this drug or its ingredients or in patients with untreated hypocalcemia. During treatment, gastrointestinal adverse reactions such as gastritis, diarrhea, abdominal pain, dyspepsia, nausea, constipation, as well as musculoskeletal adverse reactions including musculoskeletal pain, arthralgia, and myalgia may occur. Systemic and nervous system adverse reactions such as flu-like symptoms, headache, rash, and fatigue have been reported in some patients, typically mild to moderate, and recover without treatment interruption. There is a risk of osteonecrosis of the jaw during the administration of this medication, so especially patients with cancer or those with certain risk factors should undergo dental examinations before administration and avoid excessive dental procedures during treatment. Additionally, rare side effects such as external auditory canal osteonecrosis have been reported, making it important to immediately inform healthcare professionals if any abnormal symptoms in the ear occur. This medication may temporarily lower calcium levels, so hypocalcemia or bone metabolism disorders should be addressed before administration, and adequate calcium and vitamin D intake is necessary. If severe pain occurs in muscles, joints, or the skeleton, it is essential to consult healthcare professionals immediately as the possibility of atypical fractures, such as femoral fractures, may need to be evaluated in case of pain onset. The safety of this medication in pregnant or breastfeeding women has not been established, and its use is not recommended. This medication is metabolized in the kidneys, not the liver, so caution is needed in patients with impaired renal function, and regular monitoring is required. In cases of overdose, toxicity can manifest in the kidneys and liver, necessitating careful monitoring and appropriate treatment. This medication should not be mixed with calcium-containing solutions or other intravenous medications, and must be diluted with the specified solution for intravenous administration. After use, the injection needle and syringe should not be reused and must be disposed of safely.

Side effects

Gastritis, diarrhea, abdominal pain, dyspepsia, nausea, constipation, musculoskeletal pain, arthralgia, myalgia, influenza-like illness, fatigue, headache, rash, bone pain, weakness, injection site reaction, phlebitis, thrombophlebitis, allergic reaction, angioedema, facial swelling, edema, urticaria, osteonecrosis of the jaw and external auditory canal, uveitis, episcleritis, scleritis, anaphylactic reaction, shock, asthma exacerbation, Stevens-Johnson syndrome, erythema multiforme, bullous dermatitis, atypical femoral fractures, atypical fractures of the iliac bone, sensory impairment, acute renal failure, dizziness, optic nerve atrophy, lower motor neuron lesions, tremor, unspecified gastrointestinal disease, benign gastrointestinal neoplasm, toothache, hyperventilation, cough, dyspnea, laryngitis, vulvitis, menopausal symptoms, multiple organ failure, death, insomnia, anxiety, tinnitus, hearing loss, hypothyroidism, lipoma, ocular hemorrhage, heart failure, urinary disorders, hematuria, skin exfoliation

Not everyone experiences these, and they can vary from person to person.

Storage

This medication must be stored in a sealed container to prevent exposure to air or moisture. It is best to maintain the storage temperature between 1 and 30 degrees Celsius at room temperature. This helps to preserve the effectiveness and safety of the medication for a longer period.

Appearance and packaging

Appearance

A colorless, transparent solution contained in a colorless, transparent glass prefilled syringe with a single-use injection needle attached.

Package unit

3 mL/prefilled syringe (1 vial)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.